Ask an Expert
Bengaluru | 21 January 2026: Bioforum The Data Masters launched its India operations on January 21, 2026, establishing Bioforum India and a dedicated Global Capability Centre. The Israel-based biometric CRO is addressing growing client demand for scalable clinical data management and biostatistics expertise across pharmaceutical and biotech sectors.
Dr Santhosh Kumar has been appointed Senior Vice President, India & GCC, bringing 23 years of experience from leadership positions at IQVIA, Accenture Life Sciences R&D, Indegene, and Ephicacy. His mandate is to build operations that mirror Bioforum’s quality standards while expanding the company’s global delivery capacity.
“Expanding to India allows us to broaden our delivery capabilities and scale with our clients’ needs across regions and time zones. Santhosh brings the leadership experience needed to build a high-performing India operation with the rigor and quality Bioforum is known for.”
– Amir Malka, Co-Founder & CEO, Bioforum
“India is a key market for building specialized delivery capability and expanding global coverage. I’m excited to establish Bioforum India and develop a GCC that strengthens our ability to deliver consistent, high-quality support to clients worldwide.”
– Dr Santhosh Kumar, SVP, India & GCC, Bioforum
Reasons CROs Choose India
India delivers three core advantages: specialized talent, cost efficiency, and 24/7 coverage. The country produces nearly a third of the global STEM workforce, creating deep talent pools in biostatistics, statistical programming, and clinical data management.
Operating costs run 40-50% below U.S. levels while maintaining FDA and EMA quality standards. For small biotech and emerging pharma companies, this combination provides access to premium services without premium pricing.
Bioforum’s India GCC complements existing operations in Israel, the United States, Australia, and South Africa. This geographic spread enables round-the-clock support and rapid team scaling critically as trials grow more complex and time sensitive.
The Strategic Context: India’s GCC Evolution
India hosts over 1,700 Global Capability Centres, representing roughly 55% of the worldwide total. The ecosystem is projected to exceed 2,100 centres by 2028, employing 2.5 to 3 million professionals. These centres have evolved well beyond back-office cost plays. Modern GCCs function as innovation hubs driving product development, research, and operational excellence across industries.
Bengaluru dominates with 35-40% of India’s GCC base, over 870 centres concentrated in the city. The combination of infrastructure, engineering talent, and progressive state policies makes it the preferred location for life sciences operations.
The life sciences sector specifically is expanding fast. Major CROs including Quantitate, Novotech, and Phastar have established significant operations in Bengaluru, Mumbai, and Pune, recognizing India’s pharmaceutical industry maturity and regulatory expertise.
Industry Perspective: Building Capability, Not Just Capacity
We view Bioforum’s India launch as evidence of how specialized GCCs are maturing into strategic capability hubs. These centres now generate intellectual capital that directly impacts drug development outcomes, not just process transactions.
For life sciences organizations, the decision to build in India centres on enterprise resilience and access to specialized talent that drives innovation. The competitive landscape demands more than cost savings. Quality, regulatory readiness, and domain expertise separate leaders from followers.
Bioforum’s choice to build proprietary capability rather than rely on third-party providers reflects best practices for protecting quality and maintaining competitive edge. We expect this approach to become the template for other life sciences companies evaluating India operations.
Success requires three elements: leadership with proven track records, robust quality systems from day one, and full integration into global delivery networks. Companies that invest early secure advantages in talent acquisition and client delivery as the market matures.
The broader trend we’re tracking is GCCs transitioning from support functions to innovation engines. In life sciences, this means centres that contribute to study design and develop proprietary methodologies, not just execute protocols. As pharma companies increasingly outsource biometric services to manage costs and access expertise, providers that deliver consistent quality and scale efficiently will win.
Curated by SSF Global to track developments shaping the future of GCCs, enterprise ecosystems, and India’s commercial real estate landscape.
Share on 
Are you looking to set-up a GCC or expand an already existing one. Write to us and we will help you by providing the blueprint/ roadmap and SETUP solution – we are a one stop solution including end-to-end requirement for a GCC – Location, People, Process, Technology (AI) and Infrastructure.
Considering the launch or expansion of a Global Capability Centre?
Quintes Global supports enterprises with end-to-end GCC strategy and execution—from location selection and operating-model design to talent, process, AI-led technology, and infrastructure—delivering a structured blueprint for scalable, future-ready centers.
About SSF Global
SSF Global is a Global Community for Enterprise Function Leaders and serves as a research & advisory platform focused on Global Business Services (GBS), Global Capability Centres (GCCs), and the evolution of enterprise innovation in India and beyond. We track, publish, and partner in narratives that shape how capability centres transform into hubs of trust, intelligence, and sustainable growth. We also evaluate, assess and benchmark the GCCs for their performance, maturity and other parameters using our proprietary tools built from the knowledge gained from direct interaction with our members (GCCs & GBS).
